Literature DB >> 19491911

Connective tissue diseases: What does the death of Riquent hold for the future of SLE?

Joan T Merrill, Jill P Buyon.   

Abstract

In clinical trials testing new treatments for systemic lupus erythematosus (SLE), the failure of the 15-year drug development program for riquent (abetimus sodium) is the latest in a string of disappointments for a disease that has seen no new drugs approved in over 50 years.

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19491911     DOI： 10.1038/nrrheum.2009.99

Source DB:  PubMed          Journal:  Nat Rev Rheumatol        ISSN： 1759-4790            Impact factor:   20.543


  8 in total

1.  Pharmacokinetics of high-dose abetimus sodium in normal subjects with specific assessment of effect on coagulation.

Authors:  Matthew D Linnik; Anne M O'Rourke; Mark A Crowther
Journal:  J Clin Pharmacol       Date:  2008-05-29       Impact factor: 3.126

2.  Treatment of systemic lupus erythematosus with LJP 394.

Authors:  R A Furie; J M Cash; M E Cronin; R S Katz; M H Weisman; C Aranow; M R Liebling; N P Hudson; C M Berner; S Coutts; H A de Haan
Journal:  J Rheumatol       Date:  2001-02       Impact factor: 4.666

Review 3.  Newer therapeutic approaches for systemic lupus erythematosus: immunosuppressive agents.

Authors:  Mary Anne Dooley; Ellen M Ginzler
Journal:  Rheum Dis Clin North Am       Date:  2006-02       Impact factor: 2.670

4.  Baseline characteristics of a multiethnic lupus cohort: PROFILE.

Authors:  G S Alarcón; G McGwin; M Petri; J D Reveille; R Ramsey-Goldman; R P Kimberly
Journal:  Lupus       Date:  2002       Impact factor: 2.911

5.  Abetimus sodium for renal flare in systemic lupus erythematosus: results of a randomized, controlled phase III trial.

Authors:  Mario H Cardiel; James A Tumlin; Richard A Furie; Daniel J Wallace; Tenshang Joh; Matthew D Linnik
Journal:  Arthritis Rheum       Date:  2008-08

6.  LJP 394 for the prevention of renal flare in patients with systemic lupus erythematosus: results from a randomized, double-blind, placebo-controlled study.

Authors:  Donato Alarcón-Segovia; James A Tumlin; Richard A Furie; James D McKay; Mario H Cardiel; Vibeke Strand; Robert G Bagin; Matthew D Linnik; Bonnie Hepburn
Journal:  Arthritis Rheum       Date:  2003-02

Review 7.  Neonatal lupus syndromes.

Authors:  J P Buyon
Journal:  Am J Reprod Immunol       Date:  1992 Oct-Dec       Impact factor: 3.886

8.  Influence of functional interleukin 10/tumor necrosis factor-alpha polymorphisms on interferon-alpha, IL-10, and regulatory T cell population in patients with systemic lupus erythematosus receiving antimalarial treatment.

Authors:  Patricia López; Jesús Gómez; Catuxa Prado; Carmen Gutiérrez; Ana Suárez
Journal:  J Rheumatol       Date:  2008-06-15       Impact factor: 4.666
  8 in total
  2 in total

1.  The Biomarkers of Lupus Disease Study: A Bold Approach May Mitigate Interference of Background Immunosuppressants in Clinical Trials.

Authors:  Joan T Merrill; Fred Immermann; Maryann Whitley; Tianhui Zhou; Andrew Hill; Margot O'Toole; Padmalatha Reddy; Marek Honczarenko; Aikaterini Thanou; Joe Rawdon; Joel M Guthridge; Judith A James; Sudhakar Sridharan
Journal:  Arthritis Rheumatol       Date:  2017-06       Impact factor: 10.995

Review 2.  Treatment of systemic lupus erythematosus: new therapeutic avenues and blind alleys.

Authors:  Aikaterini Thanou; Joan T Merrill
Journal:  Nat Rev Rheumatol       Date:  2013-10-08       Impact factor: 20.543
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.